. 2019 Jan 31;60(2):64–74. doi: 10.4111/icu.2019.60.2.64

Table 1. Characteristics of eligible studies.

Trial	Year	Country	ACH regimens	ACH dose (mg/m²)	No. of planned cycles	Recruitment period	Pathologic stage	Total patients (ITT)		Median follow-up (IQR)
Trial	Year	Country	ACH regimens	ACH dose (mg/m²)	No. of planned cycles	Recruitment period	Pathologic stage	Control (RC only)	Treatment (RC+ACH)	Median follow-up (IQR)
Skinner et al. [26]	1991	USA	CAP	C 100, A 60, P 600	4	1980–1988	T3-4, Nany, M0	52	50	Overall: 168 mo
Freiha et al. [14]	1996	USA	CMV	C 100, M 30, V 4	4	1986–1993	T3b-4, Nany, M0	28	27	Overall: 62 mo (26.94)
Lehmann et al. [15]	2006	Germany	MVAC or MVEC	M 30, V 3, A 40, C 70	3	1987–1990	T3-4a, Nany, M0	23	26	Control: 57 mo
Lehmann et al. [15]	2006	Germany	MVAC or MVEC	M 30, V 3, E 45, C 70	3	1987–1990	T3-4a, Nany, M0	23	26	Treatment: 54 mo
Sternberg et al. [18]	2015	Europe and Canada	MVAC or GC	M 30, V 3, A 30, C 70	4	2002–2008	T3-4, Nany, M0	143	141	Control: 7.2 yr (5.6.8.7)
Sternberg et al. [18]	2015	Europe and Canada	MVAC or GC	G 1000, C 70	4	2002–2008	T3-4, Nany, M0	143	141	Treatment: 7 yr (5.2.8.7)

ACH, adjuvant chemotherapy; ITT, intent-to-treat; RC, radical cystectomy; IQR, interquartile range; CAP, cisplatin, doxorubicin and cyclophosphamide; CMV, cisplatin, methotrexate and vinblastine; MVAC, methotrexate, vinblastine, doxorubicin and cisplatin; MVEC, methotrexate, vinblastine, epirubicin and cisplatin; GC, gemcitabine and cisplatin; C, cisplatin; A, doxorubicin; P, cyclophosphamide; M, methotrexate; V, vinblastine; E, etoposide; G, gemcitabine.